Literature DB >> 9926830

Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive-compulsive disorder (OCD).

H Szechtman1, W Sulis, D Eilam.   

Abstract

Rats treated chronically with the dopamine agonist quinpirole (0.5 mg/kg, twice weekly x 10) met 5 criteria for performance of compulsive checking. Specifically, in a large open-field with single small objects in 4 of 25 locales, quinpirole rats revisited two places/objects excessively often and rapidly, compared with other locations in the environment or saline controls. They performed a ritual-like set of behavioral acts at these two places/objects and stopped in relatively few locales before returning to the preferred places/objects. Finally, they shifted their behavior to a new location when the object was moved there. Clomipramine (10 mg/kg, daily) postponed but did not prevent the development of the quinpirole effect. Quinpirole-induced compulsive checking may be an exaggeration of normal checking of home site in rats. Results suggest an animal model of obsessive-compulsive disorder and a role for dopamine in this disorder.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9926830     DOI: 10.1037//0735-7044.112.6.1475

Source DB:  PubMed          Journal:  Behav Neurosci        ISSN: 0735-7044            Impact factor:   1.912


  75 in total

Review 1.  Animal models of anxiety disorders.

Authors:  Joachim D K Uys; Dan J Stein; Willie M U Daniels; Brian H Harvey
Journal:  Curr Psychiatry Rep       Date:  2003-08       Impact factor: 5.285

Review 2.  [Deep brain stimulation for neurological and psychiatric diseases: animal experiments on effect and mechanisms].

Authors:  C Winter; D Harnack; A Kupsch
Journal:  Nervenarzt       Date:  2010-06       Impact factor: 1.214

3.  Separate mechanisms for development and performance of compulsive checking in the quinpirole sensitization rat model of obsessive-compulsive disorder (OCD).

Authors:  Mark C Tucci; Anna Dvorkin-Gheva; Renee Sharma; Leena Taji; Paul Cheon; John Peel; Ashley Kirk; Henry Szechtman
Journal:  Psychopharmacology (Berl)       Date:  2014-02-28       Impact factor: 4.530

4.  The role of dopamine in reinforcement: changes in reinforcement sensitivity induced by D1-type, D2-type, and nonselective dopamine receptor agonists.

Authors:  Natalie A Bratcher; Valeri Farmer-Dougan; James D Dougan; Byron A Heidenreich; Paul A Garris
Journal:  J Exp Anal Behav       Date:  2005-11       Impact factor: 2.468

5.  Differential effects of clorgyline on sensitization to quinpirole in rats tested in small and large environments.

Authors:  Anna Dvorkin; Kirsten E Culver; Henry Szechtman
Journal:  Psychopharmacology (Berl)       Date:  2006-05-11       Impact factor: 4.530

Review 6.  Peromyscus maniculatus bairdii as a naturalistic mammalian model of obsessive-compulsive disorder: current status and future challenges.

Authors:  De Wet Wolmarans; Isabella M Scheepers; Dan J Stein; Brian H Harvey
Journal:  Metab Brain Dis       Date:  2017-12-06       Impact factor: 3.584

7.  Clorgyline-induced modification of behavioral sensitization to quinpirole: effects on local cerebral glucose utilization.

Authors:  Toni L Richards; Thomas L Pazdernik; Beth Levant
Journal:  Brain Res       Date:  2007-05-31       Impact factor: 3.252

8.  Basal local cerebral glucose utilization is not altered after behavioral sensitization to quinpirole.

Authors:  Toni L Richards; Thomas L Pazdernik; Beth Levant
Journal:  Neurosci Lett       Date:  2007-10-18       Impact factor: 3.046

9.  Dopamine receptor supersensitivity: an outcome and index of neurotoxicity.

Authors:  Richard M Kostrzewa; John P Kostrzewa; Ryszard Brus
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

10.  Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.

Authors:  Stefano Pallanti; Silvia Bernardi; Sarah Antonini; Nikhilesh Singh; Eric Hollander
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.